Contineum officer plans $155K CTNM stock sale

Contineum Therapeutics, Inc. (CTNM) is the issuer for a planned resale of common stock by officer Daniel Lorrain under Rule 144.

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. (CTNM) is the issuer for a planned resale of common stock by officer Daniel Lorrain under Rule 144. The notice covers 9,520 common shares, with an aggregate market value of $154,604.80, expected to be sold through Morgan Stanley Smith Barney LLC on or about September 1, 2026. The shares consist of 5,350 shares underlying stock options and 4,170 shares from restricted stock units originally granted on May 9, 2017. The filing also lists multiple prior Rule 10b5-1 plan sales of CTNM common stock over the preceding three months.

Key Figures

Shares to be sold: 9,520 shares of common stock Aggregate market value: $154,604.80 Shares from stock options: 5,350 shares +3 more

6 metrics

Shares to be sold 9,520 shares of common stock Planned Rule 144 sale around September 1, 2026

Aggregate market value $154,604.80 Value of 9,520 CTNM common shares covered by Form 144

Shares from stock options 5,350 shares Common shares underlying stock options to be sold on 09/01/2026

Shares from restricted stock units 4,170 shares Common shares from RSUs granted on 05/09/2017 to be sold

10b5-1 sale on 06/30/2026 28,826 shares for $462,288.02 Prior three-month 10b5-1 sale of CTNM common stock

10b5-1 sale on 07/01/2026 8,353 shares for $132,290.08 Prior three-month 10b5-1 sale of CTNM common stock

Key Terms

Rule 144, 10b5-1, Restricted Stock Units, Exercise of Stock Options

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for DANIEL LORRAIN ... | Common | 06/30/2026"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Restricted Stock Units financial

"Common | 05/09/2017 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Exercise of Stock Options financial

"Common | 09/01/2026 | Exercise of Stock Options | Issuer"

FAQ

What does the Form 144 filing disclose for Contineum Therapeutics (CTNM)?

It discloses that officer Daniel Lorrain has notified of a planned Rule 144 resale of 9,520 CTNM common shares, with an aggregate market value of $154,604.80, to be sold through Morgan Stanley Smith Barney LLC on or about September 1, 2026.

How many Contineum Therapeutics (CTNM) shares are covered by this Form 144?

The notice covers 9,520 CTNM common shares. These include 5,350 shares issuable upon exercise of stock options and 4,170 shares from restricted stock units granted on May 9, 2017.

What is the aggregate market value of CTNM shares in this Form 144?

The aggregate market value of the 9,520 CTNM common shares covered by the notice is $154,604.80, as of the planned sale date of September 1, 2026 on NASDAQ.

How will the Contineum Therapeutics (CTNM) shares be sold under this Form 144?

The common shares are expected to be sold through Morgan Stanley Smith Barney LLC, listed in the filing as the broker, with the securities to be sold on NASDAQ around September 1, 2026.

What prior 10b5-1 plan sales by Daniel Lorrain in CTNM are disclosed?

Disclosed Rule 10b5-1 sales of CTNM common stock include, among others, 28,826 shares for $462,288.02 on June 30, 2026 and 8,353 shares for $132,290.08 on July 1, 2026, plus several smaller transactions in July and August 2026.

Who is the selling security holder in this Contineum Therapeutics (CTNM) Form 144?

The selling security holder is Daniel Lorrain, identified as an officer of Contineum Therapeutics, Inc. The Form 144 is filed for sales of CTNM common stock beneficially owned for his account.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:37 PM Accepted by SEC EDGAR 09/01/2026 - 04:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001861550
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Contineum Therapeutics, Inc.
SEC File Number	001-42001
Address of Issuer	3565 General Atomics Court, Suite 200 San Diego CALIFORNIA 92121
Phone	8583335280
Name of Person for Whose Account the Securities are To Be Sold	Daniel Lorrain
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9520	154604.80	32958632	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2026	Exercise of Stock Options	Issuer			5350	09/01/2026	Cash
Common	05/09/2017	Restricted Stock Units	Issuer			4170	05/09/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	08/03/2026	9520	151792.08
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	07/31/2026	127	2032.00
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	07/09/2026	25	400.00
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	07/08/2026	1015	16240.00
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	07/01/2026	8353	132290.08
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	06/30/2026	28826	462288.02

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/23/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Lorrain
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)